Ignacio Braña, Marta Loredo, Juan Carlos Torre-Alonso, Rubén Queiro
{"title":"VITACORA- 19和PsAID问卷对于评估银屑病关节炎对患者生活质量的影响同样有效。","authors":"Ignacio Braña, Marta Loredo, Juan Carlos Torre-Alonso, Rubén Queiro","doi":"10.1007/s10067-025-07446-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). We aimed to compare the VITACORA-19 and PsAID (Psoriatic Arthritis Impact of Disease) questionnaires to assess QoL in routine PsA management.</p><p><strong>Methods: </strong>Cross-sectional analysis of a randomly selected PsA population. Disease activity was estimated using the DAPSA (Disease Activity score for PsA) index and HRQoL using the VITACORA-19 and PsAID. The construct validity of VITACORA-19 was analysed (Pearson correlation and ROC curves).</p><p><strong>Results: </strong>Forty-five patients were included, 24 men and 21 women, mean age 55 ± 13 years, mean disease duration 8.2 ± 6.1 years. Most patients showed adequate disease control, median DAPSA 11.3 (IQR: 8.0-19.3), median PsAID 2.7 (IQR: 1.1-5.0). VITACORA-19 scores ranged from 6 to 94. The correlation between VITACORA-19 and PsAID was high, r: -0.7 (95%CI: -0.84 to -0.46), p < 0.0001. A VITACORA-19 score in the range of 6-29 corresponded to high DAPSA disease activity, a range of 30-44 corresponded to moderate DAPSA activity and a range of 45-95 corresponded to low DAPSA activity. The cut-off for an acceptable symptomatic state (PsAID < 4) corresponded to a VITACORA-19 score ≥ 66 with an area under the ROC curve of 0.85 (95%CI: 0.71-0.98).</p><p><strong>Conclusions: </strong>This is the first study comparing the VITACORA-19 and PsAID questionnaires. Either of the two questionnaires could be used to assess HRQoL in PsA. For the first time, VITACORA-19 thresholds are defined that identify the different DAPSA activity categories. A VITACORA-19 score ≥ 66 could be an appropriate treatment target. Key Points • Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). • The PsAID and VITACORA-19 questionnaires offer similar performance for assessing HRQoL in PsA. • A VITACORA-19 ≥ 66 identifies the low disease impact state according to the PsAID. • VITACORA-19 thresholds identifying DAPSA categories are reported.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The VITACORA- 19 and PsAID questionnaires are equally valid for assessing the impact of psoriatic arthritis on patients' quality of life.\",\"authors\":\"Ignacio Braña, Marta Loredo, Juan Carlos Torre-Alonso, Rubén Queiro\",\"doi\":\"10.1007/s10067-025-07446-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). We aimed to compare the VITACORA-19 and PsAID (Psoriatic Arthritis Impact of Disease) questionnaires to assess QoL in routine PsA management.</p><p><strong>Methods: </strong>Cross-sectional analysis of a randomly selected PsA population. Disease activity was estimated using the DAPSA (Disease Activity score for PsA) index and HRQoL using the VITACORA-19 and PsAID. The construct validity of VITACORA-19 was analysed (Pearson correlation and ROC curves).</p><p><strong>Results: </strong>Forty-five patients were included, 24 men and 21 women, mean age 55 ± 13 years, mean disease duration 8.2 ± 6.1 years. Most patients showed adequate disease control, median DAPSA 11.3 (IQR: 8.0-19.3), median PsAID 2.7 (IQR: 1.1-5.0). VITACORA-19 scores ranged from 6 to 94. The correlation between VITACORA-19 and PsAID was high, r: -0.7 (95%CI: -0.84 to -0.46), p < 0.0001. A VITACORA-19 score in the range of 6-29 corresponded to high DAPSA disease activity, a range of 30-44 corresponded to moderate DAPSA activity and a range of 45-95 corresponded to low DAPSA activity. The cut-off for an acceptable symptomatic state (PsAID < 4) corresponded to a VITACORA-19 score ≥ 66 with an area under the ROC curve of 0.85 (95%CI: 0.71-0.98).</p><p><strong>Conclusions: </strong>This is the first study comparing the VITACORA-19 and PsAID questionnaires. Either of the two questionnaires could be used to assess HRQoL in PsA. For the first time, VITACORA-19 thresholds are defined that identify the different DAPSA activity categories. A VITACORA-19 score ≥ 66 could be an appropriate treatment target. Key Points • Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). • The PsAID and VITACORA-19 questionnaires offer similar performance for assessing HRQoL in PsA. • A VITACORA-19 ≥ 66 identifies the low disease impact state according to the PsAID. • VITACORA-19 thresholds identifying DAPSA categories are reported.</p>\",\"PeriodicalId\":10482,\"journal\":{\"name\":\"Clinical Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10067-025-07446-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07446-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
The VITACORA- 19 and PsAID questionnaires are equally valid for assessing the impact of psoriatic arthritis on patients' quality of life.
Background and aims: Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). We aimed to compare the VITACORA-19 and PsAID (Psoriatic Arthritis Impact of Disease) questionnaires to assess QoL in routine PsA management.
Methods: Cross-sectional analysis of a randomly selected PsA population. Disease activity was estimated using the DAPSA (Disease Activity score for PsA) index and HRQoL using the VITACORA-19 and PsAID. The construct validity of VITACORA-19 was analysed (Pearson correlation and ROC curves).
Results: Forty-five patients were included, 24 men and 21 women, mean age 55 ± 13 years, mean disease duration 8.2 ± 6.1 years. Most patients showed adequate disease control, median DAPSA 11.3 (IQR: 8.0-19.3), median PsAID 2.7 (IQR: 1.1-5.0). VITACORA-19 scores ranged from 6 to 94. The correlation between VITACORA-19 and PsAID was high, r: -0.7 (95%CI: -0.84 to -0.46), p < 0.0001. A VITACORA-19 score in the range of 6-29 corresponded to high DAPSA disease activity, a range of 30-44 corresponded to moderate DAPSA activity and a range of 45-95 corresponded to low DAPSA activity. The cut-off for an acceptable symptomatic state (PsAID < 4) corresponded to a VITACORA-19 score ≥ 66 with an area under the ROC curve of 0.85 (95%CI: 0.71-0.98).
Conclusions: This is the first study comparing the VITACORA-19 and PsAID questionnaires. Either of the two questionnaires could be used to assess HRQoL in PsA. For the first time, VITACORA-19 thresholds are defined that identify the different DAPSA activity categories. A VITACORA-19 score ≥ 66 could be an appropriate treatment target. Key Points • Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). • The PsAID and VITACORA-19 questionnaires offer similar performance for assessing HRQoL in PsA. • A VITACORA-19 ≥ 66 identifies the low disease impact state according to the PsAID. • VITACORA-19 thresholds identifying DAPSA categories are reported.
期刊介绍：
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
